Differential impact of incrementally elevated CA 19-9 levels on prognosis of resected pancreatic ductal adenocarcinoma
HPB · 2024-10 · 26 (10) · 1237-1247
DOI: 10.1016/j.hpb.2024.06.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift HPB, 2024-10. Verfasst von Manish S Bhandare und 9 weiteren Autor:innen. Beteiligte Einrichtung: Gastrointestinal and Hepato-Pancreato-Biliary Service, Department of Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumba…. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, CA-19-9 Antigen, Pancreatic Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: CA 19-9 is an extremely useful biomarker for pancreatic ductal adenocarcinomas (PDACs). However, the optimal cut-off and prognostic significance at higher cut-offs are yet to be determined. METHODS: Retrospective analysis included patients with PDAC who underwent curative resection from January 2010 to May 2020 at Tata Memorial Centre, Mumbai. The pretherapy CA 19-9 was dichotomized using various cut-off levels and analysed. RESULTS: In 244 included patients, the median overall survival (OS) for those with CA19-9 level (IU/ml) 78, 200, 500, 1000, and 2000 was 27, 24, 23, 22, 21 months versus 18, 16, 15, 14, 13 months; respectively, and was statistically significant (p-value- 0.002, 0.001, 0.002, 0.002 and 0.004, respectively). The number of recurrences and mortality had significant correlation with CA 19-9 cut-offs. On multivariate analysis, adjuvant treatment completion (p-0.004) and decreasing or stable CA19-9 after Neoadjuvant therapy (NAT) (p- 0.031) were associated with improved OS. CONCLUSION: The prognostic significance of CA 19-9 was observed at all the cut-off levels examined, beyond mere elevated value as per the standard cut-off level. In patients with high CA19-9 level, surgery should be offered if technically and conditionally feasible, only when a response in CA19-9 level to NAT is achieved.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Gastrointestinal and Hepato-Pancreato-Biliary Service, Department of Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai 400012, Maharashtra, India. Electronic address: manishbhandare@gmail…
- Gastrointestinal and Hepato-Pancreato-Biliary Service, Department of Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai 400012, Maharashtra, India.
- Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
- Clinical Research Secretariat, Tata Memorial Hospital, Mumbai, India.
- Department of Radiation Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Parel, Mumbai, Maharashtra, India.
Zitieren
APA
Bhandare, M. S., Gupta, V., Chaudhari, V., Nandy, K., Ostwal, V., Ramaswamy, A., Nashikkar, C., Engineer, R., Krishnatry, R., & Shrikhande, S. V. (2024). Differential impact of incrementally elevated CA 19-9 levels on prognosis of resected pancreatic ductal adenocarcinoma. HPB, 26(10), 1237-1247. https://doi.org/10.1016/j.hpb.2024.06.004
Vancouver
Bhandare MS, Gupta V, Chaudhari V, Nandy K, Ostwal V, Ramaswamy A, et al. Differential impact of incrementally elevated CA 19-9 levels on prognosis of resected pancreatic ductal adenocarcinoma. HPB. 2024;26(10):1237-1247. doi:10.1016/j.hpb.2024.06.004
BibTeX
@article{Bhandare2024,
author = {Bhandare, Manish S and Gupta, Vikas and Chaudhari, Vikram and Nandy, Kunal and Ostwal, Vikas and Ramaswamy, Anant and Nashikkar, Chaitali and Engineer, Reena and Krishnatry, Rahul and Shrikhande, Shailesh V},
title = {Differential impact of incrementally elevated CA 19-9 levels on prognosis of resected pancreatic ductal adenocarcinoma},
journal = {HPB},
year = {2024},
volume = {26},
number = {10},
pages = {1237--1247},
doi = {10.1016/j.hpb.2024.06.004}
}
EUVIMED